- Home
- LI vs GKOS Comparison
LI vs GKOS Comparison
Compare LI & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LI | GKOS |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 9.7B |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LI | GKOS |
|---|---|---|
| Price | $11.20 | $224.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 13 |
| Target Price | $14.98 | ★ $199.31 |
| AVG Volume (30 Days) | ★ 2.5M | 979.8K |
| Earning Date | 11-25-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $0.54 | $36.30 |
| Revenue Next Year | $25.18 | $23.25 |
| P/E Ratio | $29.50 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $10.67 | $80.91 |
| 52 Week High | $20.95 | $191.62 |
Technical Indicators
Market Signals| Indicator | LI | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 45.53 | 82.74 |
| Support Level | $10.67 | $147.72 |
| Resistance Level | $11.95 | N/A |
| Average True Range (ATR) | 0.28 | 6.95 |
| MACD | 0.02 | 4.03 |
| Stochastic Oscillator | 17.24 | 94.32 |
Price Performance
Historical ComparisonAbout LI Li Auto Inc.
Li Auto is one of China's leading new energy vehicle manufacturers. Founded in 2015, the company designs, develops, manufactures, and sells premium smart NEVs with a particular focus on family size premium SUVs and MPVs. Li Auto started volume production of its first model—the Li One, an SUV that is a premium plug-in electric vehicle- in November 2019. Besides PHEVs, its product portfolio now extends to EVs that are fully battery-powered, reaching a wide audience. It has sold over 400,000 NEVs in 2025, accounting for about 3% of China's passenger NEV market.
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.